ROCKVILLE, Md. -- Intradigm Corporation, a leader in RNAi application in vivo, has obtained results showing that newly developed siRNA agents selective for specific SARS viral genes can inhibit viral infection and replication in cell based studies showing up to 90 percent inhibition of the virus. The results were obtained from a collaboration that includes Qiagen and Top Biotech, Ltd (Hong Kong).
In the studies performed, a large number of siRNA agents directed toward genes throughout the SARS coronavirus genome were designed by Qiagen and Intradigm, synthesized by Qiagen, and tested in non-human primate cells exposed to SARS virus. The results reveal which SARS viral sequences provide the best targets for inhibition of viral infection and replication and in addition, strong synergistic effects of inhibiting several targets simultaneously. The results provide strong evidence that the siRNA agents developed are specific and potent agents for inhibition of SARS coronavirus.
Intradigm has developed systemic and local siRNA delivery technologies for knocking down disease genes in animals and has validated in in-vivo models the therapeutic potentials of siRNA agents for treatment of cancer, viral infection and other unmet clinical needs. Using effective airway delivery of siRNA duplexes specific to SARS coronavirus, a single stranded RNA virus, may represent a novel approach to treat the deadly infection. Intradigm has established collaboration for development of siRNA based anti-SARS therapy with scientists in National Institute of Allergy and Infectious Diseases (NIAID) of the United States and in Hong Kong and Guangzhou of China.
John Spears, chairman and CEO of Intradigm said, "We are very excited to see this result, which is further evidence that the utilization of siRNA may potentially enable rapid identification and development of anti-viral therapeutics. We are looking forward to working with Qiagen and our other partners for further development of siRNA based therapeutics."
The in-vitro studies were conducted in laboratories in Hong Kong and Guangzhou, China, sponsored by Guangdong provincial government and Top Biotech, Ltd (Hong Kong) where the scientific teams, led by professors Nanshan Zhong, Baojian Li and Bojian Zheng, are composed of scientists from Guangzhou Medical University, Zhongshan University, Hong Kong University and Top Biotech, Ltd. Intradigm's scientific team has worked closely with these Chinese collaborators.
Intradigm Corporation is a privately held Delaware corporation that is discovering and developing therapeutic products by applying proprietary in vivo RNAi delivery technologies.
Source: Intradigm Corporation
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.